Cargando…

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group

Coronavirus disease 2019 (COVID-19) is a heterogeneous clinical condition caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The initial stage of infection occurs at the time of respiratory viral invasion through angiotensin-converting enzyme 2 (ACE2) receptors in alve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moraleda, Jose M., Carlo-Stella, Carmelo, Garcia-Bernal, David, Jara Rubio, Ruben, Andreu, Enriqueta, Calabretta, Eleonora, Aghemo, Alessio, Diaz-Ricart, Maribel, Palomo, Marta, Carreras, Enric, Vlodavsky, Israel, Iacobelli, Massimo, Fareed, Jawed, Castro, Pedro, Fernandez, Sara, Mo, Clifton C., Weinhouse, Gerald L., Cooke, Kenneth R., Soiffer, Robert J., Baron, Rebecca M., O'Gorman, Peter, Yanik, Gregory, Pagliuca, Antonio, Richardson, Paul G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	332.Anticoagulation and Antithrombotic Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330162/ http://dx.doi.org/10.1182/blood-2020-141872

Ejemplares similares

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
por: Yanik, Gregory A, et al.
Publicado: (2021)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
por: Camille, Simard, et al.
Publicado: (2020)

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients
por: Mughal, Mohsin Sheraz, et al.
Publicado: (2020)

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
por: Kodama, Rich, et al.
Publicado: (2020)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality
por: Cerezo Manchado, Juan Jose, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial
por: Gonzalez-Ochoa, Alejandro
Publicado: (2021)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”
por: Richardson, Edward, et al.
Publicado: (2020)

Rapid ECMO Training for Nurses in Response to the COVID-19 Pandemic
por: Toy, B., et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy
por: García‐Bernal, David, et al.
Publicado: (2021)

Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host disease
por: García‐Bernal, David, et al.
Publicado: (2020)

Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
por: Palomo, Marta, et al.
Publicado: (2019)

Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide
por: Martinez-Sanchez, Julia, et al.
Publicado: (2019)

The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae
por: Richardson, Paul G., et al.
Publicado: (2021)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome
por: Kernan, Nancy A., et al.
Publicado: (2018)

Defibrotide Therapy for SARS-CoV-2 ARDS
por: Frame, David, et al.
Publicado: (2022)

Endothelial Dysfunction in Hematopoietic Cell Transplantation
por: Palomo, Marta, et al.
Publicado: (2019)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting
por: Tappe, William, et al.
Publicado: (2020)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

Defibrotide in the treatment of hepatic veno-occlusive disease
por: Fulgenzi, Alessandro, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients
por: Corbacioglu, Selim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_77q9g2j8t9e1l4ri9ll4qh9t72